Actively Recruiting

Phase 2
Age: 18Years - 60Years
FEMALE
NCT07454915

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

Led by PapiVax Biotech, Inc. · Updated on 2026-05-06

138

Participants Needed

10

Research Sites

113 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this Phase 2 study is to compare the effects of administering the PVX4 combination device biologic product (pBI-4 DNA vaccine via electroporation-mediated intramuscular delivery with the TriGrid™ Delivery System) in patients with biopsy-confirmed, human papilloma virus (HPV) 16-associated high grade cervical intraepithelial neoplasia (CIN2/3) as compared to the administration of placebo.

CONDITIONS

Official Title

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

Who Can Participate

Age: 18Years - 60Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female subjects aged 18 to 60 years with biopsy-confirmed high grade cervical intraepithelial neoplasia (CIN2/3) confirmed by central review
  • HPV16 positive by Roche Cobas genotyping test; co-infections with other HPV types allowed
  • HIV negative
  • Able and willing to comply with study procedures and available for one-year follow-up
  • Of childbearing potential and agree to remain sexually abstinent, use contraception, or have a sterile partner through 6 months
  • Adequate organ function defined by specific blood counts and liver/kidney function parameters at enrollment
Not Eligible

You will not qualify if you...

  • Pregnant, breastfeeding, or attempting pregnancy within 6 months
  • Immunodeficiency or treatment with immunosuppressive medications
  • Received any blood product within 3 months prior to enrollment
  • Received any licensed vaccine within 2 weeks prior (4 weeks for live vaccines)
  • Participation in another investigational study within 30 days prior to consent
  • History of seizures unless seizure-free for 5 years
  • Cancer history within past 5 years except localized skin cancer
  • Chemotherapy, radiation, biological cancer therapy, or investigational agents within 28 days prior to first dose
  • Surgery within 28 days prior, excluding minor procedures
  • Uncontrolled illnesses affecting compliance
  • Active autoimmune diseases
  • Previous cervical conization, LEEP procedure, or total hysterectomy due to cervical lesions
  • High-grade lesions covering more than 180 degrees of cervix
  • Positive HBV or HCV PCR if seropositive
  • Incomplete lesion observation by colposcopy or positive high-grade disease by endocervical curettage
  • Adenocarcinoma in situ or certain abnormal Pap or biopsy findings
  • Less than two acceptable injection sites due to muscle mass or skin conditions
  • Contraindication to intramuscular injections or blood draws
  • Presence of metal implants or electronic stimulation devices at injection sites
  • Employment or family relation to study investigators
  • Vulnerable populations such as incarcerated individuals or those under legal protection measures

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Montefiore Medical Center

The Bronx, New York, United States, 10467

Not Yet Recruiting

2

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung, Taiwan, Taiwan, 83301

Not Yet Recruiting

3

China Medical University Hospital

Taichung, Taiwan, Taiwan, 40447

Not Yet Recruiting

4

Taichung Veterans General Hospital

Taichung, Taiwan, Taiwan, 40705

Not Yet Recruiting

5

National Cheng Kung University Hospital

Tainan, Taiwan, Taiwan, 70403

Not Yet Recruiting

6

National Taiwan University Hospital

Taipei, Taiwan, Taiwan, 100225

Not Yet Recruiting

7

MacKay Memorial Hospital

Taipei, Taiwan, Taiwan, 10449

Not Yet Recruiting

8

Taipei Medical University Hospital

Taipei, Taiwan, Taiwan, 11031

Not Yet Recruiting

9

Taipei Veterans General Hospital

Taipei, Taiwan, Taiwan, 11217

Not Yet Recruiting

10

Linkou Chang Gung Memorial Hospital

Taoyuan, Taiwan, Taiwan, 33305

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here